anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects. Peripheral neuropathy can lead to peripheral nerve damage and decreased activity, which affects the patient's quality of life. Currently, there is no standard and effective method for treating peripheral neuropathy caused by chemotherapy. Therefore, the purpose of this study is to investigate the effect of percutaneous electrical acupoint stimulation on improving peripheral nerve symptoms in breast cancer patients undergoing chemotherapy. An experimental study design will be adopted. A convenient sample of 86 patients with breast cancer who completed the chemotherapy course within one month will be recruited from outpatient clinics of a medical center in the middle district of Taiwan. Patients who are eligible and agree to participate will be randomly assigned to the transcutaneous electrical acupoint stimulation group or the control group. The transcutaneous electrical acupoint stimulation group will receive 4 weeks of transcutaneous electrical acupoint stimulation intervention, while the control group will not receive any measures related to this study. Data from both groups will be collected at the time of admission, the 1st week, the 2nd week, the 3rd week, and the 4th week. The study instruments include the cancer treatment-related quality of life neurotoxicity assessment subscale, Total Neuropathy Score clinical version, Brief Pain Inventory interference items scores and hand and foot pain Numerical Rating Scale. The obtained data will be statistically analyzed using SPSS software. The baseline equilibrium of the subjects' demographic and disease characteristics will be examined by the Chi-square test and independent sample T-test. For the main outcome variable Neurotoxicity Subscale and the Numerical Rating Scale for Hand and Foot Pain, generalized estimating equations were used to analyze the effects of between-group, time-to-group, and time-interaction effects. One-way analysis of variance (The Analysis of Variance, ANOVA) to examine intra- and inter-group differences between the clinical version of the Integrated Neuropathy Score and the Simple Pain Scale Interference Item score pretest and posttest (week 4).
The invention relates to a traditional Chinese medicine composition for treating functional constipation and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw material medicines: radix Paeoniae alba, Atractylodis rhizoma, radix rehmanniae, fructus Aurantii Immaturus parched with bran, cortex Magnolia officinalis, and fructus Cannabis. The invention also provides application of the traditional Chinese medicine in preparing a medicine for treating functional constipation. Its advantages are: 1. the selected raw material medicines are appropriate in cold and warm, and appropriate in moistening dryness, and are communicated with the tonifying, so that the effects of tonifying spleen, clearing heat, nourishing yin, moistening dryness, promoting qi circulation and clearing hollow viscera are achieved. 2. The compatibility of the traditional Chinese medicine composition for treating functional constipation conforms to the principle of 'monarch, minister, assistant and guide' of traditional Chinese medicines, and the traditional Chinese medicine composition has the advantages of fewer medicine ingredients, high curative effect, no toxic or side effect, low cost and the like. 3. The selected raw material medicines and the proportion thereof are screened by tests, and the invention has the advantage of remarkable effect. 4. The traditional Chinese medicine composition can effectively improve constipation symptoms of functional constipation (intestinal excess heat syndrome), traditional Chinese medicine symptoms and life quality, is safe to apply in a short term, and has low adverse reaction.
OBJECTIVES: I. Determine the rate and duration of complete and partial remission in patients with recurrent B-cell chronic lymphocytic leukemia treated with gemcitabine. II. Assess the toxicities of this regimen in these patients.

OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
This study is a multicenter, single arm, open, non-randomized, dose-escalation/ expansion phase Ib/II clinical study. The dose-escalation part of phase Ib clinical trial was conducted according to the Bayesian Optimal Interval Design (BOIN), with a total of three dose groups: low, medium, and high. Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID. The number of patients in each group is 3, with a maximum sample size of 9, to evaluate the safety and effectiveness of the medication, and to provide a basis for recommended phase II dose (RP2D). Eligible subjects received medication on the first day and then entered a 21 day observation period of dose-limiting toxicity (DLT). DLT is defined as the occurrence of level 3 non hematological toxicity or level 4 hematological toxicity. Evaluate the efficacy every 6 weeks. In this study, an independent Data Safety Monitoring Committee (DSMC) and an Independent Review Committee (IRC) were established to regularly review the safety and effectiveness data of each research center, with the aim of protecting subjects safety, ensuring the reliability of clinical trials and the objectivity of trial results.
Gemfibrozil tablets, USP is a lipid regulating agent. It is available as tablets for oral administration. The chemical name is 5-(2,5-dimethylphenoxy)2,2-dimethylpentanoic acid, with the following structural formula:

The molecular formula is C15H22O3 and the molecular weight is 250.33. It is soluble in alcohol, methanol and chloroform. The melting point is 58° to 61°C. Gemfibrozil is a white, waxy, crystalline solid which is stable under ordinary conditions.

Each gemfibrozil tablet intended for oral administration contains 600 mg of gemfibrozil. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, methyl cellulose and microcrystalline cellulose. Additionally each tablet contains opadry II white 33F28398 which contains hypromellose, lactose monohydrate, polyethylene glycol, talc and titanium dioxide.
PROBLEM TO BE SOLVED: To obtain the subject patch by percutaneously administering indomethacin and an extracted solution and/or its essence of Iris germancia Lam, exhibiting more excellent analgesic action than separative use of each component. SOLUTION: This patch is obtained by formulating (A) indomethacin with (B) one or more selected from the group consisting of an extracted solution of Iris germancia Lam and its essence. For example, an extract (with water, a mixed solution of water/an alcohol or an alcohol) of rhizome of Iris germancia Lam, a plant of the genus Iris of the family Iridaceae is preferably used as the component A. A patch is formulated with 0.01-5.0wt.% of the component A and 1 pt.wt. of the component A is formulated with 0.001-10 pts.wt. of the component B (calculated as raw crude medicine).
In the intervention group, each participant will receive a structured education and be asked to follow a 12-week personalized diet and daily routine protocol based on the assessment of their current Ayurvedic mind-body state. Participants will be asked to complete the self-reported questionnaires at baseline, 6, and 12-week.
Both tolerance and physical dependence can develop during use of opioid therapy.

Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.

Do not abruptly discontinue NUCYNTA ER in a patient physically dependent on opioids. Rapid tapering of NUCYNTA ER in a patient physically dependent on opioids may lead to serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse.

When discontinuing NUCYNTA ER, gradually taper the dosage using a patient-specific plan that considers the following: the dose of NUCYNTA ER the patient has been taking, the duration of treatment, and the physical and psychological attributes of the patient. To improve the likelihood of a successful taper and minimize withdrawal symptoms, it is important that the opioid tapering schedule is agreed upon by the patient. In patients taking opioids for an extended period of time at high doses, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper [see Dosage and Administration (2.6), Warnings and Precautions (5.3)].

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations (8.1)].
Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge.

The physician should instruct relatives accordingly.

The patient must be fully informed of the disulfiram-alcohol reaction. He must be strongly cautioned against surreptitious drinking while taking the drug, and he must be fully aware of the possible consequences. He should be warned to avoid alcohol in disguised forms, i.e., in sauces, vinegars, cough mixtures, and even in aftershave lotions and back rubs. He should also be warned that reactions may occur with alcohol up to 14 days after ingesting disulfiram.
OBJECTIVE: Circadian rhythm disruption (CRD) has been associated with inflammation and immune disorders, but its role in SLE progression is unclear. We aimed to investigate the impact of circadian rhythms on immune function and inflammation and their contribution to SLE progression to lupus nephritis (LN).
METHODS: This study retrospectively analysed the clinical characteristics and transcriptional profiles of 373 samples using bioinformatics and machine-learning methods. A flare risk score (FRS) was established to predict overall disease progression for patients with lupus. Mendelian randomisation was used to analyse the causal relationship between CRD and SLE progression.
RESULTS: Abnormalities in the circadian pathway were detected in patients with SLE, and lower enrichment levels suggested a disease state (normalised enrichment score=0.6714, p=0.0062). The disruption of circadian rhythms was found to be closely linked to lupus flares, with the FRS showing a strong ability to predict disease progression (area under the curve (AUC) of 5-year prediction: 0.76). The accuracy of disease prediction was improved by using a prognostic nomogram based on FRS (AUC=0.77). Additionally, Mendelian randomisation analysis revealed an inverse causal relationship between CRD and SLE (OR 0.6284 (95% CI 0.3630 to 1.0881), p=0.0485) and a positive causal relationship with glomerular disorders (OR 0.0337 (95% CI 1.634e-3 to 6.934e-1), p=0.0280).
CONCLUSION: Our study reveals that genetic characteristics arising from CRD can serve as biomarkers for predicting the exacerbation of SLE. This highlights the crucial impact of CRD on the progression of lupus.
Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
PROBLEM TO BE SOLVED: To obtain an antifungal agent, comprising a Camellia sinensis L. saponin as an active ingredient and having high selective toxicity to dermal pathogenic molds and high safety for human bodies. SOLUTION: This antifungal agent comprises a Camellia sinensis L. saponin as an active ingredient. The leaf saponin of the Camellia sinensis L. is preferably obtained from a leaf or a seed of the Camellia sinensis L. and prepared by carrying out the defatting treatment of, e.g. the leaf or the seed of the Camellia sinensis L. with an organic solvent, then extracting the leaf or seed with a hydrous lower alcohol, subsequently performing the extraction treatment of the resultant extract solution with ethyl acetate, removing catechins and then treating the prepared extract by silica gel chromatography.  The seed saponin of the Camellia sinensis L. is obtained by dissolving a commercially available crude seed saponin of the Camellia sinensis L. in water, acidifying the solution with hydrochloric acid or acetic acid, then adding ether or chloroform thereto, forming a precipitate, subsequently washing the formed precipitate with water and then recrystallizing the precipitate in a hydrous lower alcohol solution. When the objective antifungal agent is a parenteral agent, it is preferably administered in a daily dose so as to provide 10 to several hundreds μg active ingredient in one to several divided portions.
INTRODUCTION: Obesity patients undergoing laparoscopic bariatric surgery (LBS) are frequently encountered perioperative adverse events related to opioids-based anaesthesia (OBA) or opioids-free anaesthesia (OFA). While modified opioid-sparing anaesthesia (MOSA) has been shown to lower the occurrence of adverse events related to OBA and OFA. This study is to assess the efficacy of MOSA in enhancing the recovery quality among individuals undergoing LBS.
METHODS AND ANALYSIS: A single-centre, prospective, double-blind, randomised controlled trial is conducted at a tertiary hospital. A total of 74 eligible participants undergoing elective LBS will be recruited and randomly allocated. Patients in the MOSA group will receive a combination of low-dose opioids, minimal dexmedetomidine, esketamine and lidocaine, while in the OBA group will receive standard general anaesthesia with opioids. Patients in both groups will receive standard perioperative care. The primary outcome is the quality of recovery-15 score assessed at 24 hours after surgery. Secondary outcomes include pain levels, anxiety and depression assessments, gastrointestinal function recovery, perioperative complication rates, opioid consumption and length of hospital stay.
ETHICS AND DISSEMINATION: Ethical approval has been provided by the Ethical Committee of Yan'an Hospital of Kunming City (approval No. 2023-240-01). Eligible patients will provide written informed consent to the investigator. The outcomes of this trial will be disseminated in a peer-reviewed scholarly journal.
TRIAL REGISTRATION NUMBER: The study protocol is registered at https://www.chictr.org.cn/ on 19 December 2023. (identifier: ChiCTR2300078806). The trial was conducted using V.1.0.
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca ++  signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.
Fenugreek seeds have been employed for edible use as well as a material for extracting galactomannan, essential oil, oleoresin, saponin, proteins, 4-hydroxyisoleucine, etc. therefrom. These substances are extracted exclusively from seeds. In case of chemical extraction, however, all of these substances can be hardly extracted at the same time, since different extraction solvents should be employed for galactomannan and other substances. In addition, a large amount of an alcohol is needed in extracting galactomannan, which makes the product expensive compared with other galactomannan-type thickeners such as guar gum. A method of preparing an albumen powder containing galactomannan at a high purity which comprises separating albumen from seed coat with a grinder mill by taking advantage of the difference in hardness between albumen and seed coat, then milling the albumen in an impact mill or an air-stream mill to give particles with different sizes and then classifying them through a sieve. Thus, it becomes possible to separate galactomannan exclusively by the physical procedures. As a result, all effective components contained in seed coat can be obtained simultaneously and the production cost of fenugreek galactomannan can be successfully cut down.
The invention discloses liquid shampoo containing common nostoc extracts. The liquid shampoo comprises the following raw materials: the common nostoc extracts, ammonium laureth sulfate, ammonium lauryl sulfate, cocoalkanoylamido propyl betaine, sodium lauroamphoacetate, dipalmitoyl yloxyethyl dimethyl ammonia chloride, cocamidopropyl MEA (mono etobaccool amine), glycol distearate, EDTA (ethylene diamine tetraacetic acid) disodium, polyethylene glycol-14M, guar hydroxypropyltrimonium chloride, poly quaternary ammonium salt-10, cetanol, allantoin, 2 (hydrogenated tallow) phthalic acid amide, sodium chloride, kazon, panthenol, dioscorea villosa root extracts, emulsified silicone oil and essence. Solvent is water. By the liquid shampoo containing the common nostoc extracts, hair of a user can be moisturized, smooth and glossy. The invention also provides a preparation method of the liquid shampoo containing the common nostoc extracts. The preparation method is simple and effective; and the production cost can be reduced.
NEW MATERIAL:A compound shown by formula I [R<1> is (substituted) 8-20C chain hydrocarbon group or polyether chain group having sum of (substituted) carbons and oxygen of 8-20 atoms; R<2> is substituent group-containing CH3 or (substituted) cyclic group], a compound shown by formula IV or a salt thereof. EXAMPLE:3-Cyclopropyl-1-octyl-2-pyrazolin-5-one. USE:A drug. An inhibitor of formation of peroxy lipid or lipoxygenase inhibitor and collagenase inhibitor, having low toxicity and side effects, useful for treating and preventing diseases such as diseases of circulatory organs, inflammations, allergies, etc., and cancer metastatis. PREPARATION:1mol beta-keto-acid derivative shown by formula II (R<3> is 1-5C alkyl) is reacted with 1-3mol hydrazine derivative shown by formula III in a solvent such as ethanol under cooling with ice-100 deg.C for about 30 minutes - 15 hours to give a compound shown by formula I or formula IV. The compound shown by formula IV is isolated and heated to give a compound shown by formula I.
This study unveils the pivotal roles of taurine metabolic reprogramming and its implications in the development and progression of Abdominal Aortic Aneurysm (AAA). Leveraging an integrated approach that combines single-cell RNA sequencing (scRNA-seq) and Weighted Gene Co-expression Network Analysis (WGCNA), our research investigates the intricate transcriptional and gene expression dynamics crucial to AAA. Our findings uniquely link metabolic shifts to the integrity of the extracellular matrix (ECM) and the functionality of smooth muscle cells (SMCs), key elements in the pathology of AAA. Utilizing scRNA-seq data from a mouse model (GSE152583 dataset), we identified critical alterations in cellular composition during AAA progression, particularly highlighting shifts in fibroblasts and inflammatory cells. Concurrently, WGCNA of human AAA tissue samples has outlined distinct gene expression patterns correlated with disease severity and progression, offering comprehensive insights into both molecular and cellular disease mechanisms. Moreover, this study introduces innovative metabolic profiling techniques to identify differential metabolites in AAA, integrating extensive metabolomic analyses with pathway enrichment strategies. This novel approach has pinpointed potential biomarkers and therapeutic targets, notably within taurine metabolism pathways, crucial for crafting non-surgical interventions. By merging state-of-the-art bioinformatics with thorough molecular analysis, our study not only enhances the understanding of AAA's complex pathophysiology but also catalyzes the development of targeted therapeutic strategies. This research represents a significant advancement in the molecular characterization of AAA, with substantial implications for its future diagnosis and treatment strategies.
PURPOSE: To obtain an angiogenesis inhibitor containing benzoyl carbinol or its ester, useful for treatment of chronic inflammation, diabetic retinopathy, psoriasis, chronic arthrorheumatism, hyperplasia of cancers or the like. CONSTITUTION: This inhibitor contains, as the active ingredient, a compound shown by formula I  R is H or shown by formula II [R1 is a 1-6C alkyl or shown by formula III (R2 and R3 are each H, a 1-6C alkyl or 5-6C cycloalkyl, or forms a monoheterocyclic structure together with a chemically bound N atom)]} or a medically permissible salt thereof, e.g. benzoyl carbinol trimethylacetate. The above salt can be formed by the reaction with an inorganic acid, e.g. hydrochloric, sulfuric or phosphoric acid or the like, or an organic acid, e.g. tartaric, citric or methanesulfonic acid or the like, to improve solubility of the compound in water, making the inhibitor more adaptable, e.g. to intramuscular injection.